SCHEMBL20023010

SCHEMBL20023010

O=C(COc1ccc(Cl)cc1)C(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS5 Q9UNA0 4/20 0.52
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ GPR183 P32249 1/20 0.51
▸ NR4A2 P43354 2/20 0.50
▸ MRGPRX4 Q96LA9 1/20 0.49
▸ GPR34 Q9UPC5 1/20 0.48
▸ ADAMTS4 O75173 1/20 0.48
▸ AR P10275 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ PLA2G4B P0C869 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ PTGES O14684 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20022957 0.89 ALOX15 (0.53) KMT2AMEN1NR4A2TP53MAPT
SCHEMBL20022989 0.86 TAAR1 (0.50) ADAMTS5KMT2AMEN1NR4A2MRGPRX4
SCHEMBL20023012 0.85 MRGPRX4 (0.53) ADAMTS5KMT2AMEN1MRGPRX4ALDH1A1
SCHEMBL20023046 0.85 RXRA (0.53) KMT2AMRGPRX4POLBKDM4ENPC1
SCHEMBL20382458 0.80 S1PR1 (0.47) KMT2AMEN1MRGPRX4MAPTALDH1A1
SCHEMBL7425728 0.80 TAAR1 (0.52) KMT2AMEN1NR4A2MRGPRX4TP53
SCHEMBL7639146 0.80 L3MBTL1 (0.54) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL16527831 0.79 SRD5A2 (0.57) ADAMTS5KMT2AMEN1NR4A2MRGPRX4
SCHEMBL7061713 0.78 PLAAT3 (0.57) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL9786937 0.77 NR4A2 (0.66) NR4A2MRGPRX4MAPTPLA2G4BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 — — US disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors ASAH2, GBA1, GAA ADAMTS5 1790/4885KMT2A 1937/4885MEN1 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback